These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39587053)

  • 1. Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial.
    Shiozawa M; Sunakawa Y; Watanabe T; Ota H; Yasui H; Yabuno T; Tei M; Kochi M; Manaka D; Ohori H; Yamaguchi T; Sagawa T; Kotaka M; Kubota Y; Sekikawa T; Nakamura M; Takeuchi M; Ichikawa W; Fujii M; Tsuji A
    Nat Commun; 2024 Nov; 15(1):10217. PubMed ID: 39587053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study.
    Yamamoto Y; Yukami H; Yamaguchi T; Ohori H; Nagasu S; Kagawa Y; Sugimoto N; Sonoda H; Yamazaki K; Takashima A; Okuyama H; Hasegawa H; Kondo C; Baba E; Matsumoto T; Kawamoto Y; Kataoka M; Shindo Y; Ishikawa T; Esaki T; Kito Y; Sato T; Funakoshi T; Yamaguchi T; Shimada Y; Moriwaki T
    Int J Clin Oncol; 2024 Dec; 29(12):1878-1886. PubMed ID: 39196470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study.
    Chen Y; Zhu D; Yu Y; Chang W; Ye L; Feng Q; Xu P; Chen M; Ji M; Wei Y; Liu T; Xu J
    Clin Colorectal Cancer; 2024 Dec; 23(4):354-363.e4. PubMed ID: 38845274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy and radiotherapy for advanced pancreatic cancer.
    Haggstrom L; Chan WY; Nagrial A; Chantrill LA; Sim HW; Yip D; Chin V
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD011044. PubMed ID: 39635901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study.
    Klein-Scory S; Baraniskin A; Schmiegel W; Mika T; Schroers R; Held S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Stintzing S; Heinemann V
    Mol Oncol; 2024 Dec; ():. PubMed ID: 39630848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study.
    Sekmek S; Ozsan Çelebi SN; Bayram D; Erol C; Kos FT; Sendur MAN; Altıntas YE; Tuylu T; Yildirim S; Biter S; Kıdı MM; Bayram E; Majidova N; Bayoglu IV; Atak M; Baskurt K; Akbas S; Alkan A; Bayramgil A; Aslan F; Sahin E; Balcik OY; Bayhan AZ; Saray S; Arpaci E; Ergun Y
    Sci Rep; 2024 Nov; 14(1):29785. PubMed ID: 39616250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort.
    Tougeron D; Bibeau F; Chibaudel B; Kim S; Nguyen T; Phelip JM; Mille D; Bouattour M; Tavan D; Rinaldi Y; Lecomte T; Perrier H; Spaeth D; Caroli Bosc FX; Metges JP; Ferec M; Hautefeuille V; Deslandres-Cruchant M; Danion J; Hammel P; Lewin M; Tasu JP; Angelergues A; DiFiore F; Evrard S; Mansar R; Caillou H; Geffriaud-Ricouard C; Adam R
    Eur J Cancer; 2024 Dec; 213():115082. PubMed ID: 39486163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar monoclonal antibodies for cancer treatment in adults.
    Galvao TF; Livinalli A; Lopes LC; Zimmermann IR; Silva MT
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD013539. PubMed ID: 39607013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer.
    Tseng KY; Yang MY; Chen WS; Jiang JK; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Yang YW; Lin YZ; Chang CY; Teng HW
    Int J Colorectal Dis; 2024 Dec; 39(1):195. PubMed ID: 39630293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EGFR Rechallenge in Metastatic Colorectal Cancer and the Role of ctDNA: A Systematic Review and Meta-analysis.
    da Silva LFL; Saldanha EF; da Conceição LD; Noronha MM; da Silva MVMG; Peixoto RD'
    J Gastrointest Cancer; 2024 Dec; 56(1):28. PubMed ID: 39623250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explanatory Role of Conversion Surgery as a Mediator of the Mortality Risk Difference Between Patients With Unresectable Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR Agents Versus Bevacizumab.
    Su CC; Su YC; Wu CC; Lee PT
    Clin Colorectal Cancer; 2024 Dec; 23(4):364-371. PubMed ID: 38879376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial.
    Ma LX; Titmuss E; Loree JM; Jonker DJ; Kennecke HF; Berry S; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski S; Tu D; O'Callaghan C; Chen EX
    J Immunother Cancer; 2024 Dec; 12(12):. PubMed ID: 39631846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study.
    Li B; Yang W; Liu N; Bi D; Yang T; Wu G; Sun Y
    Br J Cancer; 2024 Dec; 131(11):1775-1780. PubMed ID: 39448860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.
    Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C
    Hepatol Int; 2024 Aug; 18(4):1286-1298. PubMed ID: 38717693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
    Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
    PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.
    Wang Q; Yu J; Sun X; Li J; Cao S; Han Y; Wang H; Yang Z; Li J; Hu C; Zhang Y; Jin L
    Crit Rev Oncol Hematol; 2024 Dec; 204():104522. PubMed ID: 39332750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of prognostic nutritional index on laboratory parameters and survival in metastatic colorectal cancer patients treated with fruquintinib: a retrospective study.
    Wang Z; Zhao S; Zhang X; Mao X; Yang G; Yuan M; Zhou X
    PeerJ; 2024; 12():e18565. PubMed ID: 39624124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
    Llovet JM; Kudo M; Merle P; Meyer T; Qin S; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Masi G; Kwiatkowski M; Lim HY; Kim JH; Breder V; Kumada H; Cheng AL; Galle PR; Kaneko S; Wang A; Mody K; Dutcus C; Dubrovsky L; Siegel AB; Finn RS;
    Lancet Oncol; 2023 Dec; 24(12):1399-1410. PubMed ID: 38039993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.